Cancer is the Leading Cause of Death Worldwide

Breakthrough Discoveries,  Renegade Scientists, and Patients Fighting Cancer
That We Find Inspiring

Dragonfly's Proprietary TriNKETs Activate the Body's NK Cells and Mobilize T Cells + Other Cells of the Adaptive Immune System

Dragonfly launches a Phase I study for their lead drug DF1001 in HER2 expressing solid tumors. This is the first of their TriNKET platform drugs to go into humans. 

​

Dragonfly Therapeutics Initiates Phase 1/2 Study of its IL12 Immunotherapy in Patients with Advanced Solid Tumors